Nantes

• MAINTAIN-POP: EXL01 and prevention of post-operative recurrence of Crohn's disease Recruiting
  2024-511357-22-00 4 2025-03-31 Crohn's disease
• Efficacy and safety of bezafibrate 400 mg and bezafibrate 200 mg as adjunctive treatments in patients with primary biliary cholangitis and n … Recruiting
  2023-504086-23-00 5 2025-03-27 Subjects with PBC with a non-optimal response to UDCA.
• A study to investigate changes in symptoms in adult participants with chronic rhinosinusitis with nasal polyposis initiating treatment with … Recruiting
  2024-513862-20-00 5 2025-03-26 Chronic Rhinosinusitis with Nasal Polyposis
• Ziftomenib in combination with chemotherapy for children with relapsed/refractory acute leukemia Recruiting
  2023-505262-28-00 3 2025-03-24 Acute Myeloid Leukemia
• Study to evaluate efficacy and safety of inclisiran in children aged 6 to under 12 years of age with heterozygous familial hypercholesterole … Recruiting
  2024-514594-21-00 5 2025-03-13 Heterozygous Familial Hypercholesterolemia
• MICROBIOTA MODIFICATION FOR IMMUNO-ONCOLOGY IN HEPATOCELLULAR CARCINOMA - “MOTHER” Recruiting
  2023-508201-25-00 4 2025-03-12 Hepatocellular carcinoma
• A study to assess the efficacy and safety of lumateperone in patients with major depressive disorder Recruiting
  2023-503836-41-00 5 2025-03-10 Major Depressive Disorder
• Chimiothérapie à base de bevacizumab adaptée à la pharmacocinétique du bevacizumab en 1ère ligne de traitement du cancer colorectal métastat … Recruiting
  2023-507873-16-00 11 2025-03-04 1st line treatment for unresectable metastatic colorectal cancer
• AntaMIn - Pain reduction for limb injuries in pediatric emergency departments: A Randomised Clinical Trial comparing intranasal Fentanyl or … Recruiting
  2023-506803-25-01 10 2025-02-26 urgency
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab (INCA034176) and Corticosteroids as Initial Treatment for Chroni … Recruiting
  2023-510292-65-00 5 2025-02-25 chronic graft-versus-host disease
• Open-label study of Asciminib for CML-CP or CML-AP patients with T315I mutation who are resistant, intolerant or ineligible to ponatinib Recruiting
  2024-516049-38-00 4 2025-02-18 CML-CP or CML-AP patients with T315I mutation
• A phase II, multicenter, open-label study evaluating Glofitamab in combination with Venetoclax plus Zanubrutinib or Venetoclax alone in subj … Recruiting
  2023-506706-40-00 10 2025-02-11 Mantle-Cell Lymphoma
• Beta-blOckers discoNtinuation in patients presenting heart FaIlure with REcovered left ventricular ejection fraction Recruiting
  2023-508798-94-00 5 2025-02-11 Heart failure
• NEFARTHRO - Effets précoces et tardifs du néfopam dans l'analgésie multimodale après arthroplastie totale de hanche Recruiting
  2023-504079-26-01 5 2025-02-10 Arthroplastie totale de hanche
• Multicentric Phase 1 Study With Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) or CPX-351 … Recruiting
  2022-502585-25-00 3 2025-02-06 Adult patients with adverse Risk Acute Myeloblastic Leukemia
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting
  2023-508234-34-00 4 2025-01-27 Crohn's disease
• A study to assess how Vaborem® is taking up in the body and tolerated in paediatric patients with serious infections. Recruiting
  2024-514656-32-00 4 2025-01-23 Suspected or confirmed Gram negative infections
• Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc … Recruiting
  2024-513852-13-00 5 2025-01-20 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
• Surgical treatment of large incisional hernia with botulinum toxin A injection: a double-blind randomized controlled trial Recruiting
  2023-504554-35-00 5 2025-01-17 incisional hernia
• Pembrolizumab in progressive multifocal leukoencephalopathy (PML) in immunocompromised patients without HIV infection (PENALTY) Recruiting
  2023-503520-31-00 4 2025-01-15 Immunocompromised patients with PML (with an underlying cause of immun
• Early immunotherapy with intravenous immunoglobulin, cyclophosphamide and methylprednisolone in patients with anti-Hu-associated paraneoplas … Recruiting
  2023-506942-22-01 4 2025-01-10 paraneoplastic sensory neuropathy with anti-Hu antibodies
• Safety and efficacy of apixaban versus warfarin in peritoneal dialysis patients with non valvular atrial fibrillation: a randomized controll … Recruiting
  2023-507544-37-00 5 2025-01-08 patients with end-stage renal disease on chronic peritoneal dialysis a
• ANRS0392s ELDORADO : Phase III, open-label, randomized, multicenter trial EvaLuating the non-inferiority of DORAvirine versus DOlutegravir b … Recruiting
  2023-508626-10-00 5 2025-01-08 HIV-1 infection
• EvER-ILD 3 : Evaluation of Efficacy and safety of Rituximab and mycophenolate mofetil combination in patients with Interstitial Lung Disease … Recruiting
  2023-510507-21-00 10 2025-01-08 Intersitial lung disease related to systemic sclerosis

Showing 265–288 of 787 trials